Biogen Inc (IDP.DE)

Healthcare | Drug Manufacturers General
Latest reporting period: 2025-03-31

Latest Quarter

2025-03-31

Revenue

$2.4B

Net Income

$241M

Operating Margin

25.7%

Free Cash Flow

$2.1B

Debt / Assets

38.0%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Biogen Inc (IDP.DE).
Income Statement (Quarterly) 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Revenue 2,431,000,000 2,454,700,000 2,465,800,000 2,464,900,000
Cost of Revenue 629,300,000 583,500,000 638,700,000 546,000,000
Gross Profit 1,801,700,000 1,871,200,000 1,827,100,000 1,918,900,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 572,500,000 680,000,000 588,400,000 553,800,000
Operating Expenses 1,176,500,000 1,420,600,000 1,330,700,000 1,217,000,000
Operating Income 625,200,000 450,600,000 496,400,000 701,900,000
Interest Expense 60,000,000 60,000,000 59,800,000 61,300,000
Income Before Tax 311,200,000 291,500,000 451,000,000 698,700,000
Income Tax Expense 70,700,000 24,800,000 62,500,000 115,100,000
Net Income 240,500,000 266,700,000 388,500,000 583,600,000
Per Share
EPS 1.65 1.83 2.67 4.01
EPS Diluted 0.00 0.00 0.00 0.00